Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
AssigneeAmicus Therapeutics, Inc.
InventorHUNG DO
Life of this patent
Estimating the term…
Loading patent…
AssigneeAmicus Therapeutics, Inc.
InventorHUNG DO
Estimating the term…
Described herein are methods of making targeting peptides conjugated to a recombinant lysosomal enzyme by modifying the amino (N)-terminus and one or more lysine residues on a recombinant human lysosomal enzyme using a first crosslinking agent to give rise to a first crosslinking agent modified recombinant human lysosomal enzyme, modifying a lysine or cysteine within a short extension linker at the carboxyl (C)-terminus on a variant IGF-2 peptide having a short extension linker using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short extension linker. Also described herein are conjugates synthesized using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.
1-3. (canceled)
A variant IGF-2 peptide comprising SEQ ID NO:2 or comprising the amino acid sequence of SEQ ID NO:2 that has one or more of the following modifications:
Dependencies are inferred from the claim text.